- Min.Order :10 Milligram
- Purity: ≥98%
- Payment Terms : T/T
Keywords
Equol 531-95-3 standard supplier in China
Quick Details
- Appearance:detailed see specifications
- Application:analysis,activity test,Botanical Reference Materials,Standard materials
- PackAge:According to the clients requirement.
- ProductionCapacity:1|Metric Ton|Day
- Storage:Store at 2~8°C
- Transportation:by air or by ocean shipping
Superiority:
Hubei CuiRan Biotechnology Co., Ltd is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，Traditional Chinese Medicine), Natural Active Pharmaceutical Ingredients worldwide. From small quantities for R&D or reference standard, to large quantities for customizing or manufacturing, Biopurify emphasizes on consistent and reliable services for his customers.
With excellent quality products and good service, we have clients from more than dozens countries and regions, and we pride ourselves in providing our customers with a total satisfaction experiences.
We are doing our best to be your reliable partner for high quality Phytochemicals and Reference Standards from china.
Our main services:
A. Supply active ingredients and reference standards ofTraditional Chinese Medicine, from mgs to kgs scale.
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR, CM and PD services from lab scale, pilot scale to commercial scale(GMP is also available)
E.Traditional Chinese Medicine compounds library
1.Provide traditional Chinese medicine reference materials and natural active ingredients;
2.More than 2200 compounds are available for selection, continuously building high-quality natural product libraries for drug research and development;
3.Provide various screening libraries and more inhibitor products;
4.Provide separation and structural determination of natural products;
5.Laboratory scale pilot to commercial scale collaborative research and process development services.More than 180 experiences in phytochemistry (still increasing)
Each product has passed very strict testing (NMR/MS/HPLC)
Agents from many countries
General tips：For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging：1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition：Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.
Details:
Chemical Properties of 4',7-Isoflavandiol
| Cas No. | 531-95-3 | ||
| PubChem ID | 91469 | Appearance | Powder |
| Formula | C15H14O3 | M.Wt | 242.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | DMSO : 100 mg/mL (412.76 mM; Need ultrasonic and warming) | ||
| Chemical Name | (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol | ||
| SMILES | C1C(COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O | ||
| Standard InChIKey | ADFCQWZHKCXPAJ-GFCCVEGCSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Source of 4',7-Isoflavandiol
The seeds of Glycine max
Biological Activity of 4',7-Isoflavandiol
| Description | 4',7-Isoflavandiol, an estrogen metabolite, affects the ability of soy nuts to improve cardiovascular risk factors. 4',7-Isoflavandiol is a potential anticancer agent against HeLa, with possible mechanisms involved in ROS generation and mitochondrial membrane alteration; it may advance breast cancer potential via up-regulation of the eukaryotic initiation factor 4GI (eIF4GI). |
| Targets | c-Myc | ROS | MMP(e.g.TIMP) | Bcl-2/Bax | Caspase | Estrogen receptor |
| In vitro |
Equol induces mitochondria-mediated apoptosis of human cervical cancer cells.[Pubmed: 25202081] Anticancer Res. 2014 Sep;34(9):4985-92. The present study aimed to investigate anticancer properties of 4',7-Isoflavandiol and demonstrate its underlying mechanisms of action in human cervical cancer HeLa cells. |
| In vivo |
Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome status.[Pubmed: 25441251] Metabolism. 2015 Feb;64(2):236-43. Soy has been associated with lower risk of cardiovascular disease in Asian countries which consume daily soy. Our study examined whether production of 4',7-Isoflavandiol , an estrogen metabolite, affected the ability of soy nuts to improve cardiovascular risk factors. |
Protocol of 4',7-Isoflavandiol
| Kinase Assay |
Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G.[Pubmed: 25593313] J Biol Chem. 2015 Mar 6;290(10):6047-57. Epidemiological studies implicate dietary soy isoflavones as breast cancer preventives, especially due to their anti-estrogenic properties. However, soy isoflavones may also have a role in promoting breast cancer, which has yet to be clarified. We previously reported that 4',7-Isoflavandiol, a metabolite of the soy isoflavone daidzein, may advance breast cancer potential via up-regulation of the eukaryotic initiation factor 4GI (eIF4GI). In estrogen receptor negative (ER-) metastatic breast cancer cells, equol induced elevated levels of eIF4G, which were associated with increased cell viability and the selective translation of mRNAs that use non-canonical means of initiation, including internal ribosome entry site (IRES), ribosome shunting, and eIF4G enhancers. These mRNAs typically code for oncogenic, survival, and cell stress molecules. Among those mRNAs translationally increased by 4',7-Isoflavandiol was the oncogene and eIF4G enhancer, c-Myc. |
Preparing Stock Solutions of 4',7-Isoflavandiol
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.1271 mL | 20.6356 mL | 41.2712 mL | 82.5423 mL | 103.1779 mL |
| 5 mM | 0.8254 mL | 4.1271 mL | 8.2542 mL | 16.5085 mL | 20.6356 mL |
| 10 mM | 0.4127 mL | 2.0636 mL | 4.1271 mL | 8.2542 mL | 10.3178 mL |
| 50 mM | 0.0825 mL | 0.4127 mL | 0.8254 mL | 1.6508 mL | 2.0636 mL |
| 100 mM | 0.0413 mL | 0.2064 mL | 0.4127 mL | 0.8254 mL | 1.0318 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
References on 4',7-Isoflavandiol
Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome status.[Pubmed:25441251]
Metabolism. 2015 Feb;64(2):236-43.
OBJECTIVE: Soy has been associated with lower risk of cardiovascular disease in Asian countries which consume daily soy. Our study examined whether production of equol, an estrogen metabolite, affected the ability of soy nuts to improve cardiovascular risk factors. MATERIALS/METHODS: Sixty postmenopausal women participated in a randomized, controlled, crossover trial of a Therapeutic Lifestyle Changes (TLC) diet alone and a TLC diet in which 0.5 cup of soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones) replaced 25 g of nonsoy protein daily. Each diet was followed for 8 weeks at the end of which blood pressure (BP), lipid levels, adhesion molecules and inflammatory markers were measured. RESULTS: Women with MetS had significantly higher baseline body mass index (BMI), BP, triglycerides (TG), and soluble intercellular adhesion molecule (sICAM) than women without MetS. In women with MetS on the soy diet, significant reductions in diastolic BP (7.7%; P=0.02), TG (22.9%; P=0.02), C-reactive protein (CRP) (21.4%; P=0.01) and sICAM (7.3%; P=0.03) were noted among equol producers compared to levels on the TLC diet. No significant changes were noted in equol nonproducers. Similarly, in women without MetS, only equol producers had significant reductions in diastolic BP (3.3%, P=0.02) and CRP (30%, P=0.04). In contrast to women with MetS, TG and sICAM levels were not affected in women without MetS, a finding possibly related to lower baseline levels. CONCLUSIONS: Cardiovascular risk reduction with soy nuts is not uniform and may be greater among producers of equol.
Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G.[Pubmed:25593313]
J Biol Chem. 2015 Mar 6;290(10):6047-57.
Epidemiological studies implicate dietary soy isoflavones as breast cancer preventives, especially due to their anti-estrogenic properties. However, soy isoflavones may also have a role in promoting breast cancer, which has yet to be clarified. We previously reported that equol, a metabolite of the soy isoflavone daidzein, may advance breast cancer potential via up-regulation of the eukaryotic initiation factor 4GI (eIF4GI). In estrogen receptor negative (ER-) metastatic breast cancer cells, equol induced elevated levels of eIF4G, which were associated with increased cell viability and the selective translation of mRNAs that use non-canonical means of initiation, including internal ribosome entry site (IRES), ribosome shunting, and eIF4G enhancers. These mRNAs typically code for oncogenic, survival, and cell stress molecules. Among those mRNAs translationally increased by equol was the oncogene and eIF4G enhancer, c-Myc. Here we report that siRNA-mediated knockdown of c-Myc abrogates the increase in cancer cell viability and mammosphere formation by equol, and results in a significant down-regulation of eIF4GI (the major eIF4G isoform), as well as reduces levels of some, but not all, proteins encoded by mRNAs that are translationally stimulated by equol treatment. Knockdown of eIF4GI also markedly reduces an equol-mediated increase in IRES-dependent mRNA translation and the expression of specific oncogenic proteins. However, eIF4GI knockdown did not reciprocally affect c-Myc levels or cell viability. This study therefore implicates c-Myc as a potential regulator of the cancer-promoting effects of equol via up-regulation of eIF4GI and selective initiation of translation on mRNAs that utilize non-canonical initiation, including certain oncogenes.
Equol induces mitochondria-mediated apoptosis of human cervical cancer cells.[Pubmed:25202081]
Anticancer Res. 2014 Sep;34(9):4985-92.
BACKGROUND/AIM: The present study aimed to investigate anticancer properties of equol and demonstrate its underlying mechanisms of action in human cervical cancer HeLa cells. MATERIALS AND METHODS: Inhibition of cell viability was examined by 3-(4,5-dimethylthiazoly-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was evaluated by observation of apoptotic cell morphology, and an increase of annexin-V(+) cells. Western blotting was used to examine apoptosis-related proteins. Flow cytometry was used to measure mitochondrial membrane potential (MMP) and reactive oxygen species (ROS). RESULTS: Equol treatment inhibited HeLa cell proliferation in dose- and time-dependent manner. Equol-induced apoptotic cell death was accompanied by the activation of caspases, and alteration of MMP and mitochondrial membrane proteins; equol also rapidly triggered ROS production. Pre-treatment with N-acetylcysteine blocked loss of MMP, caused increase of Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, caspase-8 activation, and apoptosis induced by equol. CONCLUSION: Equol is a potential anticancer agent against HeLa, with possible mechanisms involved in ROS generation and mitochondrial membrane alteration.
Description
(-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a Ki of 0.73 nM.
Keywords:
4',7-Isoflavandiol,531-95-3,Natural Products,Estrogen/progestogen Receptor, buy 4',7-Isoflavandiol , 4',7-Isoflavandiol supplier , purchase 4',7-Isoflavandiol , 4',7-Isoflavandiol cost , 4',7-Isoflavandiol manufacturer , order 4',7-Isoflavandiol , high purity 4',7-Isoflavandiol
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View